scholarly journals De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

2018 ◽  
Vol 18 (7) ◽  
pp. 1783-1789 ◽  
Author(s):  
R. A. Bray ◽  
H. M. Gebel ◽  
R. Townsend ◽  
M. E. Roberts ◽  
M. Polinsky ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Phase Iii ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Specific Antibodies ◽  
Donor Specific Antibodies ◽  
Post Hoc

scholarly journals Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients

Renal Failure ◽  
2019 ◽  
Vol 42 (1) ◽  
pp. 40-47 ◽  
Author(s):  
Masahiko Yazawa ◽  
Orsolya Cseprekal ◽  
Ryan A. Helmick ◽  
Manish Talwar ◽  
Vasanthi Balaraman ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Specific Antibodies ◽  
Donor Specific Antibodies

scholarly journals Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aziza Ajlan ◽  
Hassan Aleid ◽  
Tariq Zulfiquar Ali ◽  
Hala Joharji ◽  
Khalid Almeshari ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
First Year ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Double Blind ◽  
Donor Specific Antibodies

Abstract Background Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. Aims To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol. Methods Prospective, randomized, double blind, non-inferiority, controlled clinical trial Expected outcomes 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2. Secondary outcomes: a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of de novo donor-specific antibodies (DSAs) Trial registration The study has been prospectively registered at clinicaltrials.gov (NTC: 04404127). Registered on 27 May 2020.

Sign in / Sign up

Export Citation Format

Share Document